secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001549595-24-000097
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL
-------------------------------------------------------------------------------

- Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).
- Cash and marketable securities $452.5M as of May 31, 2024, up from $254.3M after $188.7M public offering.
- NX-5948 Phase 1a/b data: ORR 69.2% in heavily pretreated CLL patients; plans for pivotal trial in 2025.
- Appointed Paula O'Connor as CMO and Pasit Phiasivongsa as CTO to lead clinical and CMC operations.
- Entered into Amendment No.1 to equity distribution agreement allowing up to $150M ATM offerings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000097/0001549595-24-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000097/nrix-20240711.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer